Evidence map›Paper›PMID 33428994›Full record

ReviewAdvanced drug delivery reviews2021

Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.

Jun Chen, Xixi Zhang, Reid Millican, Jennifer Sherwood, Sean Martin, Hanjoong Jo, Young-Sup Yoon, Brigitta C Brott, Ho-Wook Jun

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 151 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Recent Advances in Nanozymes for the Treatment of Atherosclerosis.International journal of nanomedicine · 2025
    Review
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Jun ChenDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL, United States.
Xixi ZhangDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL, United States.
Reid MillicanEndomimetics, LLC., Birmingham, AL, United States.
Jennifer SherwoodEndomimetics, LLC., Birmingham, AL, United States.
Sean MartinDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL, United States.
Hanjoong JoWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, United States; Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA, United States.
Young-Sup YoonSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
Brigitta C BrottDivision of Cardiovascular Disease, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, United States.
Ho-Wook JunDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL, United States. Electronic address: hwjun@uab.edu.
University of Alabama at Birmingham · USEndomimetics (United States) · USThe Wallace H. Coulter Department of Biomedical Engineering · USYonsei University · KR

Funding

UAB Diabetes Research CenterP30DK079626 · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2025 to 2025
$1.3M
Cardiac Revascularization with Direct Reprogramming ApproachesR01HL150887 · NHLBI · EMORY UNIVERSITY · PI Young-Sup Yoon · 2022 to 2023
$898k
Dual action nanomatrix coated stent evaluation using engineered artery sheets with atherosclerotic featuresR01HL163802 · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2025 to 2025
$730k
Shear stress, endothelial miRNAs, and AV calcificationR01HL119798 · NHLBI · EMORY UNIVERSITY · PI Hanjoong Jo · 2022 to 2022
$539k
NHLBI NIH HHS R01 HL119798NHLBI NIH HHS R01 HL125391NHLBI NIH HHS R01 HL139757NHLBI NIH HHS R01 HL150887NHLBI NIH HHS R01 HL158571NHLBI NIH HHS R01 HL163802NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

Atherosclerosis is a chronic inflammatory disease driven by lipid accumulation in arteries, leading to narrowing and thrombosis. It affects the heart, brain, and peripheral vessels and is the leading cause of mortality in the United States. Researchers have strived to design nanomaterials of various functions, ranging from non-invasive imaging contrast agents, targeted therapeutic delivery systems to multifunctional nanoagents able to target, diagnose, and treat atherosclerosis. Therefore, this review aims to summarize recent progress (2017-now) in the development of nanomaterials and their applications to improve atherosclerosis diagnosis and therapy during the preclinical and clinical stages of the disease.

Indexed as

AtherosclerosisNanostructuresAnimalsHumansAtherosclerosisClinical useImaging contrast agentsNanomaterialsTheranostic agentsTherapeutic delivery system

Identifiers

PMID33428994
PMCPMC7981266
OpenAlexW3120517416

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.